Kornimate/medical-research-clean huggingface dataset:
applicability of video games and vibrational therapy in reducing pain secondary to breast cancer

Conditions: Pain

Summary: to evaluate the influence of virtual reality and vibrational therapy in reducing pain intensity secondary to breast cancer before and after application of treatment protocols, through biomedical instrumentation.

after physiotherapy assessment individuals will be randomly divided into three groups: group virtual reality - cinesioterapia (g1), group vibration therapy - cinesioterapia (g2) and control group (g3), which will be submitted to the respective treatment protocols. group virtual reality cinesioterapia (g1) participate in this group 20 women will be treated through the games xbox 360 ®, attributed to this, customized applications using virtual and augmented reality to be developed. vibration therapy group - cinesioterapia (g2) - will participate in this group 20 women who will undergo 15 minutes of continuous vibration through the blanket vibrating members higher, with frequency 40 hz, 3 function and intensity tolerable, keeping the limb supported and elevated to 120 º. at the end held muscle stretching exercises, dissociation of shoulder girdle and upper limb exercises assets. control group (g3) - participate in this group 20 women who are treated with conventional cinesioterapia through muscle stretching exercises for flexors, extensors, adductors and abductors shoulder for 20 seconds each; dissociation girdle; financial assets and active assisted for groups flexors, extensors, abductors and adductors of the upper limbs, which will be performed three sets of 10 repetitions for each exercise. implementation of treatment protocols for the groups g1, g2 and g3 will run for two weeks, being monday through friday feira.totalizando 10 consecutive treatment sessions lasting 30 minutes each session. you will be prompted to patients groups g1, g2 and g3 to respond individually and without any aid the visual numeric scale of pain, 10 minutes pre-therapy, 15 minutes after the start and 10 minutes after the end of therapy. patients will undergo the assessment of pain, electromyographic activity of muscles, muscle strength, range of motion analysis and perimetry in the first day of treatment, and after completing all the sessions patients were reassessed.

Eligibility criteria:
inclusion criteria: * women who underwent surgery for unilateral mastectomy and axillary lymphadenectomy modified in a period exceeding one year; * submit medical referral; * which are not performing radiotherapy or chemotherapy; * age 40-70 years; * reporting pain, intermittent, prolonged duration and intensity that limits the adl; * lymphedema in the ipsilateral upper limb surgery; * to agree and sign the statement of consent exclusion criteria: * individuals who fail to provide medical referral; * be a carrier of other types of cancer; * have undergone other types of surgery removal of breast cancer; - be doing chemotherapy or radiotherapy; * do not complain of pain symptoms and lymphedema; * presenting severe joint lock.

Keywords: breast cancer vibratory therapy virtual reality
detection of chromosomal aberrations in urine samples using fluorescent in situ hybridization (fish) (urovysion test)

Conditions: Bladder Cancers

Summary: the purpose of the study is the identification of chromosomal aberrations in urine samples. the imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classification of urovysion fish stained urine samples.

the fish test detect chromosomal aberrations in urine specimens from persons with hematuria suspected of having bladder cancerous using the urovysion® bladder cancer kit (urovysion kit) which is fda approved. this kit is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus. results from the urovysion kit are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.

Eligibility criteria:
inclusion criteria: * well stained slides with bright fish signals exclusion criteria: * very old slides that were already bleached

Keywords: bladder cancer chromosomal aberrations fish urine sample
the role of l-arginine in polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome; L-arginine; Gut Microbiome

Summary: pcos patients meeting the trial criteria were enrolled from the shanghai 10th people's hospital. the contents of this study were introduced to them, and they were invited to participate in the study. we further evaluated the efficacy and safety of arginine in treating pcos by implementing the l-arginine clinical intervention protocol, and conducting post-intervention follow-up, efficacy evaluation, laboratory tests, and fecal sample 16s rrna sequencing.

in this study, we will enroll pcos patients who meet the trial criteria from the shanghai 10th people's hospital, introduce the content of this study to them, and invite them to participate in the study. perform laboratory tests for pcos and collect baseline stool and blood samples. the clinical intervention program of l-arginine was implemented, and post-intervention follow-up, efficacy evaluation and laboratory examination were carried out. stool and blood samples were collected after the intervention, and 16s rrna sequencing was performed on stool samples before and after the intervention. to analyze whether pcos-related clinical and laboratory indicators improved after l-arginine treatment of pcos, and to analyze the changes in patients' microbiome before and after l-arginine treatment, to clarify the effectiveness and safety of l-arginine treatment of pcos.

Eligibility criteria:
inclusion criteria: * aged 18-45 years * diagnosis of pcos with the rotterdam diagnosis criteria (2003) exclusion criteria: * pregnant women; * hyperthyroidism or hypothyroidism * severe liver and kidney function injury * cancer patients; * associated with severe infection, severe anemia, neutropenia and other blood system diseases; * have type 1 diabetes, single-gene mutated diabetes or other secondary diabetes; * patients with mental illness or intellectual disability; * have taken drugs for pcos treatment in the last three months; * have a long history of taking hormone therapy; * currently or recently participating in another clinical trial.
uremic toxins of patients with acute kidney failure

Conditions: Kidney Failure, Acute

Summary: determination of the concentration of uremic toxins of sepsis patients with or without acute kidney failure compared to the concentrations of uremic toxins of chronically uremic patients

determination of the concentration of uremic toxins of sepsis patients with or without acute kidney failure compared to the concentrations of uremic toxins of chronically uremic patients

Eligibility criteria:
inclusion criteria: * intensive care patients with sepsis * patients with acute kidney failure: serum creatinin \> 2 mg/dl * chronic haemodialysis patients exclusion criteria: * \< 18 years
trial on the acceptability of modified lipid based nutrient supplements among malawian infants

Conditions: Malnutrition

Summary: the use of lipid-based nutrients (lns), such as nutributter or fortified spread (fs), have been associated with improved growth and development outcomes among infants in ghana and malawi. the investigators' study group has developed modified versions of such supplements that theoretically will supplement infants diets better and with lower cost. as a preparation for larger efficacy trials, the investigators now aim to test the acceptability of these supplements among malawian infants and their guardians. the trial hypothesis is that the infants will consume on average at least 50% of an offered dose that consists of lns mixed with maize porridge.

in the first phase, 18 infants meeting set criteria are randomised into receiving three test meals with novel lns preparations over a three-day period. the meals will consists of the following, each given on one day and in a random order: 1) 7.5 g of lns-10gm mixed in 30 g maize-soy porridge, 2) 15 g of lns-20gm mixed in 30 g maize-soy porridge, 3) 15 g of lns-20gnom mixed in 30 g maize-soy porridge. as a run in procedure, each participant will undergo a test feeding session with one of the the test foods on the day before the actual test-feeding period. as a positive control, each participant will undergo test feeding session with standard nutributter (nb) on the day after the actual test-feeding period. in the second phase a set of 48 infants are randomised into 3 groups receiving the following food supplements for a period of 2 weeks: 1) 10 g/day of milk-containing, very concentrated lns (lns-10gm), 2) 20 g/day of milk-containing, concentrated lns (lns-20gm), 3) 20 g/day of milk-free, concentrated lns (lns-20 g nom) outcomes measures in the first phase will be assessed through safety reports and quantities of test food consumed by the child and a hedonic scale of acceptability by the mothers of the children. the second phase will be assessed with qualitative outcomes, from data obtained from focus group discussions with the guardians of the infants consuming the test foods.

Eligibility criteria:
inclusion criteria: * signed informed consent from at least one guardian * age 7.50 months to 11.49 months * currently breastfeeding * consuming complementary feeds at least 30 days prior to enrollment * availability during the period of the study exclusion criteria: * weight for length z score (wfh) ≤ -2.0 using who growth reference standards or the -presence of oedema * severe systemic illness warranting hospital referral * history of allergy towards peanut * history of anaphylaxis or serious allergic reaction to any substance, requiring emergency medical care * congenital malformation such as cleft palate which may interfere with food intake * concurrent participation in any other clinical trial

Keywords: stunting growth failure malnutrition lipid based nutrient supplement lns prevention malawi sub-saharan africa dietary supplementation
neoadjuvant chemotherapy in locally advanced bladder cancer

Conditions: Bladder Cancer

Summary: to evaluate the efficacy and safety of neoadjuvant gemcitabine and cisplatin (gem/cis) in locally advanced bladder cancer.

patients with locally advanced transitional cell bladder cancer receive 3 cycles of neoadjuvant gemcitabine/cisplatin before radical cystectomy. patients with histologically confirmed clinical stage t2-t4a, n0-2 bladder cancer are going to be included. after ct scan of the thorax and abdomen plus mri of the pelvis patient receive chemotherapy. pathologic response rate will be assessed after surgery by the institutional pathologic review. safety is going to be assessed according to the national cancer institute common toxicity criteria (ctc,version 3.0).

Eligibility criteria:
inclusion criteria: * 18 years of age * histologically confirmed stage t2, t3 or t4a urothelial bladder cancer with n0-n2 * eastern cooperative oncology group (ecog) performance status of 0-1 * bone marrow reserve (neutrophil count \>1500 cells per μl,platelet count \>100 000 per μl) count * hepatic function (serum bilirubin \<2,5 times the upper limit of normal, serum aminotransferase ≤2,5 times the upper limit of normal). * renal function with a creatinine clearance \>60ml/min exclusion criteria: * metastatic disease * serious or uncontrolled concurrent medical illness * pregnancy * history of other malignancies (with the exception of excised cervical or basal skin or squamous-cell carcinoma) * non-transitional cell bladder cancer * creatinine clearance \<60ml/min

Keywords: bladder cancer neoadjuvant chemotherapy gem/cis
safety and pharmacology of stanate

Conditions: Hyperbilirubinemia

Summary: the purpose of this study is to evaluate the effect and safety of stanate (stannsoporfin) in infants who are at risk for an exchange transfusion and meet the criteria of the protocol.

the present study evaluated the relationship between stanate® dose, drug safety, and efficacy in a non randomised sequential open label cohort design, in 55 patients. subjects were term and near term infants at medium or high risk of hyperbilirubinemia with tsb levels approaching the threshold for exchange transfusion. the first cohort began at a dose of stannsoporfin 0.75 mg/kg of birth weight intramuscularly. the dose was then increased to 1.5 mg/kg for cohort 2, and saline was given (placebo) for cohort 3. safety evaluations consisted of hepatic, renal and hematologic clinical laboratory tests along with serial physical examinations. long term follow up of all patients to age 6 is planned.

Eligibility criteria:
inclusion criteria: * term and near-term healthy infants (may be no more than 14 days of age) with excessive hyperbilirubinemia who are at risk for exchange transfusion according to the aap guidelines of 2004 exclusion criteria: * no parental consent * major known congenital anomaly * current use of antibiotics, cardio-respiratory instability, abnormal renal function, hepatitis (as related to torch infections) * phenobarbital use in either child or mother (30 days prior to child's birth)

Keywords: neonatal jaundice hyperbilirubinemia
risk of ckd in diabetic patients with mafld

Conditions: Type 2 Diabetes

Summary: this cross-sectional study of 300 participants investigates the risk of chronic kidney disease (ckd) in individuals with metabolic dysfunction-associated fatty liver disease (mafld) and type 2 diabetes. by evaluating hepatic measurements and metabolic markers, the study aims to identify key risk factors for ckd in this population, contributing valuable insights to inform targeted interventions.

investigators plan to enroll 300 participants with type 2 dm to comprehensively investigate the risk of chronic kidney disease (ckd) in individuals diagnosed with metabolic dysfunction-associated fatty liver disease (mafld) and type 2 diabetes mellitus. in this study, the participant population will be grouped based on presence of mafld or not into 2 groups, then the group with mafld will be subdivided into subgroups based on the degree of hepatic involvement, considering both controlled attenuation parameter (cap) values for steatosis and liver stiffness measurements for fibrosis via fibro scan device. this grouping strategy aims to categorize individuals into distinct cohorts, such as low hepatic involvement and high hepatic involvement groups, facilitating a nuanced exploration of the association between hepatic conditions and the risk of chronic kidney disease (ckd) in the context of metabolic dysfunction-associated fatty liver disease (mafld) and type 2 diabetes mellitus.

Eligibility criteria:
inclusion criteria: * type 2 diabetic patients * willing and agreed to be included in the study. exclusion criteria: * type 1 diabetic patients or non-diabetic patients. * patient with known glomerulonephritis. * patient with diagnosis of or clinical features that are suspicious for another systemic disease that commonly causes kidney disease (e.g., connective tissue disorders, hiv). * patient with evidence of alternative kidney disease like (documented obstructive uropathy, etc.) * patient with history of kidney transplantation. * patient with end stage renal disease or on dialysis. * patients with active malignancy. * individuals with a history of hepatitis b surface antigen or hepatitis c antibody positivity. * history of excessive alcohol consumption (⩾30 g/day in men and ⩾20 g/day in women) * decompensated liver cirrhosis.
doula home visiting randomized trial

Conditions: Breast Feeding; Parenting; Child Development; Depression, Postpartum

Summary: the purpose of this randomized controlled trial is to examine whether evidence-based home visiting programs enhanced by doula services have effects on positive parenting practices, breastfeeding, and child and maternal health outcomes.

the goal of this study is to evaluate the impact of doula enhanced evidence-based home visiting programs for young mothers in illinois. mothers in the intervention group receive home visits from doulas during pregnancy and in the first few weeks postpartum, and doulas provide mothers with support at the hospital during labor, delivery, and with early breastfeeding. additionally, mothers in the intervention group receive prenatal and long-term postpartum home visitation services through an evidence-based home visiting program, such as parents as teachers and healthy families illinois. mothers in the comparison group receive a less intensive case management service. four existing doula home visiting programs located in economically distressed communities in illinois were selected for participation in the study. at each site, young pregnant women are recruited for participation in the study, provide informed consent, and complete a baseline interview in their homes during mid-pregnancy. at completion of the baseline interview, mothers are randomly assigned to either the doula home visiting intervention group or the case management comparison group. at 37 weeks of pregnancy, and at 3 weeks-, 3 months-, 13 months-, and 30 months, and 4 years postpartum, mothers are interviewed in their homes on topics including pregnancy, parenting, health, mental health, feeding practices, employment/education, and relationships. additionally, at all postpartum visits, mothers are videorecorded interacting with their infants. at the 13 month, 30 month, and 4 year followup sessions, children of the study participants are administered developmental and behavioral assessments. based on prior studies of doula services and the goals of doula enhanced home visiting programs, a variety of outcomes are assessed at followup time points. these outcomes include prenatal medical care, prenatal bonding with infant, feelings of efficacy during labor, anesthesia use during labor, breastfeeding, positive parenting behaviors, parenting attitudes and stress, infant health, maternal health, maternal depressive symptoms, and child behavior and development.

Eligibility criteria:
inclusion criteria: * pregnant and between 12 and 34 weeks gestation * live within the catchment area of a program site * between ages of 14-24 * english or spanish speaking exclusion criteria: * ward of the department of children and family services (dcfs) * under supervision of juvenile justice system * planning to give up custody of infant * pregnancy result of sexual assault

Keywords: doulas parenting breast feeding pregnancy in adolescence child development
relationship between gross motor coordination and balance in children with spastic cerebral palsy

Conditions: Cerebral Palsy

Summary: this study aims to determine if there is a connection between gross motor coordination and balance in children with spastic cerebral palsy. since these children often struggle with balance and other motor skills, researchers hypothesize that there is no link between the two abilities.

purpose: to examine the relationship between the gross motor coordination and balance in children with spastic cerebral palsy. background: motor coordination is required for the effective acquisition of movements and effortless performance. gross motor coordination involves numerous skills, including balance, bilateral movement, agility, and speed. children with cerebral palsy exhibit a deterioration in gross motor coordination ability. the lack of postural control in children with cerebral palsy impairs functional balance. according to studies, children with cerebral palsy have poorer static and dynamic balance responses than typically developing children. hypotheses: - there is no relationship between gross motor coordination and balance in children with spastic cerebral palsy. research question: - is there a relationship between gross motor coordination and balance in children with spastic cerebral palsy.

Eligibility criteria:
inclusion criteria: 1. they were scored level i on the gross motor function classification system (gmfcs). 2. the subjects' age was from five to eleven years. 3. they were at least 1-meter-tall and not less 20 kg. 4. they had to comprehend verbal commands. 5. they were score 1 to 1+ based on modified ashworth' scale. exclusion criteria: 1. contracture, deformity and/or tightness in upper or lower limbs. 2. botulinum toxin in the last year. 3. recent fracture. 4. vertigo or dizziness. 5. epilepsy. 6. osteoporosis. 7. recent operation in the six months at least (according to the type of operation).

Keywords: cerebral palsy balance gross motor coordination
covid-19: awake proning and high-flow nasal cannula in respiratory distress

Conditions: Coronavirus Infection; COVID; Severe Acute Respiratory Syndrome; Respiratory Failure; Respiratory Insufficiency; Respiratory Distress Syndrome; ARDS; Lung Diseases

Summary: prone positioning is an established intervention in mechanically ventilated acute respiratory distress syndrome (ards) patients, with demonstrated reductions in mortality. preliminary data suggest that awake proning in patients with covid-19 treated with high-flow nasal oxygenation (hfno) improves gas exchanges, and might be associated with a reduced need of mechanical ventilation, and reduced mortality. further investigation in a formal randomized-controlled trial is need.


Eligibility criteria:
inclusion criteria: * covid-19, either confirmed by sars-cov-2 assay, or clinically suspected, with results of the assay pending; * lung infiltrates documented on chest x-ray or chest ct-scan; * significant respiratory distress that requires treatment with hfno. exclusion criteria: * unable to consent; * unable to prone; * indication for immediate endotracheal intubation and mechanical ventilation; * contraindication to prone positioning (severe obesity, abdominal wound, pregnancy, unstable pelvic/spinal lesions, vomiting, etc.); * comfort care or imminent expectation of death.

Keywords: sars-cov-2 sars-cov-2 infection covid-19 hfnc hfno proning prone position high-flow nasal cannula high-flow nasal oxygenation acute respiratory distress syndrome